STCUBE Logo

STCUBE

Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.

052020 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 강남구 영동대로 511 2201(삼성동, 무역센터 트레이드타워), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

STCube is a clinical-stage biopharmaceutical company specializing in the development of first-in-class, precision-driven immunotherapies for cancer. The company's core focus is on its lead drug candidate, Nelmastobart, the world's first immune checkpoint inhibitor targeting the novel BTN1A1 protein. This target is highly expressed in chemo-refractory and resistant cancer cells, often in a mutually exclusive manner with PD-L1, offering a new therapeutic avenue for patients with unmet medical needs. Having successfully completed Phase 1 clinical trials confirming its safety and efficacy, Nelmastobart represents a potential treatment for various treatment-resistant cancers. STCube advances its pipeline through research, development, and biomarker-driven clinical trials, collaborating with leading global institutions and forming strategic partnerships with multinational pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.2 KB
2025-08-25 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획자진취하등) (면역항암제 hSTC810 의 미국 식품의약국(FDA) 제1b/2상 임상…
Korean 14.5 KB
2025-08-25 00:00
Regulatory News Service
투자판단관련주요경영사항(임상시험계획승인신청) (Nelmastobart(hSTC810)의 진행성/전이성 비소세포폐암 제2…
Korean 9.1 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-03-20 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험계획승인신청등결정) (면역항암제 Nelmastobart(hSTC810)의 전이성/재발성 …
Korean 13.1 KB
2025-03-19 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 29.9 KB
2025-03-19 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.7 KB
2025-03-11 00:00
Audit Report / Information
감사보고서제출
Korean 25.6 KB
2025-03-11 00:00
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
Korean 504.8 KB
2025-03-04 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 190.4 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 202.3 KB
2025-02-28 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 186.5 KB

Automate Your Workflow. Get a real-time feed of all STCUBE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for STCUBE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.